10.6084/m9.figshare.3439757
Sundar Jagannath
Sundar
Jagannath
Anuja Roy
Anuja
Roy
Jonathan Kish
Jonathan
Kish
Orsolya Lunacsek
Orsolya
Lunacsek
Denise Globe
Denise
Globe
Michael Eaddy
Michael
Eaddy
Emil T. Kuriakose
Emil T.
Kuriakose
Joanne Willey
Joanne
Willey
Stephanie Butler-Bird
Stephanie
Butler-Bird
David Siegel
David
Siegel
Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices
Taylor & Francis Group
2016
Multiple myeloma
treatment patterns
real-world evidence
relapsed/refractory
duration of therapy
progression-free survival
2016-06-16 23:09:44
Dataset
https://tandf.figshare.com/articles/dataset/Real-world_treatment_patterns_and_associated_progression-free_survival_in_relapsed_refractory_multiple_myeloma_among_US_community_oncology_practices/3439757
<p><b>Background</b>: Evidence supporting optimal treatment sequencing in relapsed/refractory multiple myeloma (RRMM) patients requiring multiple therapy lines is lacking.</p> <p><b>Methods</b>: Using retrospective chart data, this study describes real-world RRMM treatment patterns and related progression-free survival (PFS) in US community oncology clinics.</p> <p><b>Results</b>: Bortezomib ± a non-immunomodulatory drug (IMiD), lenalidomide ± a non-proteasome inhibitor (PI), bortezomib + an IMiD were the most commonly used regimens in early lines of therapy. Median PFS was similar in 1<sup>st</sup> (11.1 months) and 2<sup>nd</sup> line (10.5) and decreased in lines 3 through 5 (3<sup>rd</sup>: 7.9; 4<sup>th</sup>: 7.2, 5<sup>th</sup>: 5.4). Longest PFS (12.5 months) in first line was with bortezomib + ImiD; longest PFS in second line was with lenalidomide ± a non-PI was (13.2 months).</p> <p><b>Conclusions</b>: Re-treatment with bortezomib was common; novel agents were reserved for later therapy lines. Overall, the observed PFS associated with real-world treatment sequences were shorter than those reported in clinical trials.</p>